الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 207 |  |  |
| | | from | 207 | | |
Abstract
Chronic kidney diseases (CKD) affect millions of people in the world and they represent an important public health problem owing to the increasing incidence as well as prevalence and the high costs of treatment. The latest estimates of the World Health Organization suggested a CKD prevalence of over 10%, including end stage renal disease (ESRD).
Therefore, bone marrow and adipose tissue MSCs were tested for their ability to treat chronic kidney disease of one of well-known nephrotoxic agent; namely CsA, in spite of its use as immune suppressive drug during kidney transplantation. In addition, the study was extended to elucidate the role of stem cell versus angiotensin converting enzyme inhibitor in kidney repair. Moreover, the awareness of the nephrologists by the CsA complications will be added to the targets of this study, especially during its long term administration. This study included 64 adult female albino rats, which were divided into eight experimental groups. The MSCs therapeutic potential was evaluated by some biochemical and histopathological investigations.
In conclusion, this study demonstrates that stem cell therapy elicits angiogenesis anti-inflammatory and anti-arteriolopathic effects in a rat model of chronic CsA-induced nephropathy. Noteworthy, the preferable effect has been demonstrated by adipose tissue-derived mesenchymal stem cells. The increment of UNAG, TGF-β, eNOS, ET-1 and VEGF may be involved in the mechanisms underlying the reno-protective properties of stem cell. Moreover, our findings intense more light on the possible mechanisms by which the stem cells can ameliorate CsA-induced nephropathy and the potential rationale for its clinical use in nephropathic treatment in the future.